Dendritic cell-based vaccination for renal cell carcinoma: Challenges in clinical trials

Immunotherapy

Volumn 4, Issue 10, 2012, Pages 1031-1042

  Wang, Jin ^a   Liao, Lianming ^b   Tan, Jianming ^a  

^a XIAMEN UNIVERSITY   (China)

^b FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

cytokine induced killer cell; dendritic cell; immune monitoring; renal cell carcinoma; tumor vaccine

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD83 ANTIGEN; CD86 ANTIGEN; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; HLA DR ANTIGEN; IMMUNICUM; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; PROSTAGLANDIN E2; T6 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; CELL MIGRATION; CELL SEPARATION; CELLULAR DISTRIBUTION; DENDRITIC CELL; HUMAN; KIDNEY CARCINOMA; MONOCYTE; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; CARCINOMA, RENAL CELL; CTLA-4 ANTIGEN; DENDRITIC CELLS; HUMANS; KIDNEY NEOPLASMS; T-LYMPHOCYTES, REGULATORY; VACCINATION;

EID: 84869164521     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.107     Document Type: Review

References (95)

1. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treat. Rev. 34(3), 193-205 (2008).
2. Drucker BJ. Renal cell carcinoma: Current status and future prospects. Cancer Treat. Rev. 31(7), 536-545 (2005).
3. Geertsen PF, Gore ME, Negrier S, Tourani JM, von der Maase H. Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma. Br. J. Cancer. 90(6), 1156-1162 (2004).
4. Yang JC, Beck KE, Blansfield JA, Tran KQ, Lowy I, Rosenberg SA. Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010). J. Clin. Oncol. 23(16S), 2501 (2005).
5. Zhang RT, Bines SD, Ruby C, Kaufman HL. TroVax® vaccine therapy for renal cell carcinoma. Immunotherapy 4(1), 27-42 (2012).
6. Liu L, Zhang W, Qi X et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin. Cancer Res. 18(6), 1751-1759 (2012).
7. Figlin RA, Thompson JA, Bukowski RM et al. Multicenter, randomized, Phase III trial of CD8+ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J. Clin. Oncol. 17(8), 2521-2529 (1999).
8. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheralblood stem-cell transplantation. N. Engl. J. Med. 343(11), 750-758 (2000).
9. Takahashi Y, Childs RW. Nonmyeloablative transplantation: An allogeneic-based immunotherapy for renal cell carcinoma. Clin. Cancer Res. 10(18 Pt 2), S6353-S6359 (2004).
10. Höltl L, Rieser C, Papesh C et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J. Urol. 161(3), 777-782 (1999).
11. Schwaab T, Schwarzer A, Wolf B et al. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (interleukin 2) and IFN-a2a therapy in metastatic renal cell carcinoma patients. Clin. Cancer Res. 15(15), 4986-4992 (2009).
12. Leonhartsberger N, Ramoner R, Falkensammer C et al. Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma. Cancer Immunol. Immunother. 61(9), 1407-1413 (2012).
13. Draube A, Klein-González N, Mattheus S et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: A systematic review and meta-analysis. PLoS ONE 6(4), E18801 (2011).
14. Schlom J. Therapeutic cancer vaccines: Current status and moving forward. J. Natl Cancer Inst. 104(8), 599-613 (2012).
15. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5(4), 296-306 (2005).
16. Ueno H, Klechevsky E, Schmitt N et al. Targeting human dendritic cell subsets for improved vaccines. Semin. Immunol. 23(1), 21-27 (2011).
17. Lipscomb MF, Masten BJ. Dendritic cells: Immune regulators in health and disease. Physiol. Rev. 82(1), 97-130 (2002).
18. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 33(4), 464-478 (2010).
19. Mosca PJ, Lyerly HK, Clay TM, Morse MA, Lyerly HK. Dendritic cell vaccines. Front. Biosci. 12, 4050-4060 (2007).
20. Xiong W, Candolfi M, Liu C et al. Human Flt3L generates dendritic cells from canine peripheral blood precursors: Implications for a dog glioma clinical trial. PLoS ONE 5(6), E11074 (2010).
21. Jakobsen MA, Møller BK, Lillevang ST. Serum concentration of the growth medium markedly affects monocyte-derived dendritic cells' phenotype, cytokine production profile and capacities to stimulate in MLR. Scand. J. Immunol. 60(6), 584-591 (2004).
22. Büchler T, Kovárová L, Musilová R et al. Generation of dendritic cells using cell culture bags - description of a method and review of literature. Hematology 9(3), 199-205 (2004).
23. Baek S, Kim CS, Kim SB et al. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: Results from a Phase I/II trial. J. Transl. Med. 9, 178 (2011).
24. Harada Y, Okada-Nakanishi Y, Ueda Y et al. Cytokine-based high log-scale expansion of functional human dendritic cells from cord-blood CD34-positive cells. Sci. Rep. 1, 174 (2011).
25. Fahrer AM. A proposal for a simple and inexpensive therapeutic cancer vaccine. Immunol. Cell. Biol. 90(3), 310-313 (2012).
26. Hovden AO, Karlsen M, Jonsson R, Aarstad HJ, Appel S. Maturation of monocyte derived dendritic cells with OK432 boosts IL-12p70 secretion and conveys strong T-cell responses. BMC Immunol. 12, 2-10 (2011).
27. Feuerstein B, Berger TG, Maczek C et al. A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J. Immunol. Methods 245(1-2), 15-29 (2000).
28. John J, Hutchinson J, Dalgleish A, Pandha H. Cryopreservation of immature monocytederived dendritic cells results in enhanced cell maturation but reduced endocytic activity and efficiency of adenoviral transduction. J. Immunol. Meth. 272(1-2), 35-48 (2003).
29. Tuyaerts S, Aerts JL, Corthals J et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol. Immunother. 56(10), 1513-1537 (2007).
30. Zhou J, Weng D, Zhou F et al. Patientderived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: In vitro results and clinical responses. Cancer Immunol. Immunother. 58(10), 1587-1597 (2009).
31. Avigan DE, Vasir B, George DJ et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J. Immunother. 30(7), 749-761 (2007).
32. Höltl L, Ramoner R, Zelle-Rieser C et al. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol. Immunother. 54(7), 663-670 (2005).
33. Santegoets SJ, van den Eertwegh AJ, van de Loosdrecht AA, Scheper RJ, de Gruijl TD. Human dendritic cell line models for DC differentiation and clinical DC vaccination studies. J. Leukoc. Biol. 84(6), 1364-1373 (2008).
34. New type of dendritic-cell-based cancer vaccine enters the clinic. Hum. Vaccin. Immunother. 8(2), 152-153 (2012).
35. Garrod KR, Liu FC, Forrest LE, Parker I, Kang SM, Cahalan MD. NK cell patrolling and elimination of donor-derived dendritic cells favor indirect alloreactivity. J. Immunol. 184(5), 2329-2336 (2010).
36. Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH. Interleukin-10-treated human dendritic cells induce a melanomaantigen specific anergy in CD8+ T cells resulting in a failure to lyse tumor cells. Blood 93(5), 1634-1642 (1999).
37. Tomiyama M, Takahara M, Egawa K, Nieda M. Mature dendritic cells are superior to immature dendritic cells in expanding antigen-specific naive and memory CD8+T cells. Anticancer Res. 24(5C), 3327-3333 (2004).
38. McIlroy D, Gregoire M. Optimizing dendritic cell-based anticancer immunotherapy: Maturation state does have clinical impact. Cancer Immunol. Immunother. 52(10), 583-591 (2003).
39. Gitlitz BJ, Belldegrun AS, Zisman A et al. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J. Immunother. 26(5), 412-419 (2003).
40. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I et al. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: A Phase 1 study. J. Immunother. 25(6), 500-508 (2002).
41. Su Z, Dannull J, Heiser A et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 63(9), 2127-2133 (2003).
42. Jarnjak-Jankovic S, Hammerstad H, Saebøe-Larssen S, Kvalheim G, Gaudernack G. A full scale comparative study of methods for generation of functional dendritic cells for use as cancer vaccines. BMC Cancer 7, 119 (2007).
43. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104(8), 2235-2246 (2004).
44. Gi M, Im W, Hong S. Dendritic cells as danger-recognizing biosensors. Sensors (Basel) 9(9), 6730-6751 (2009).
45. Bürdek M, Spranger S, Wilde S, Frankenberger B, Schendel DJ, Geiger C. Three-day dendritic cells for vaccine development: Antigen uptake, processing and presentation. J. Transl. Med. 8, 90 (2010).
46. Hu Z, Liu S, Mai X, Hu Z, Liu C. Anti-tumor effects of fusion vaccine prepared by renal cell carcinoma 786-O cell line and peripheral blood dendritic cells of healthy volunteers in vitro and in human immune reconstituted SCID mice. Cell. Immunol. 262(2), 112-119 (2010).
47. Wei YC, Sticca RP, Li J et al. Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study. Oncol. Rep. 18(3), 665-671 (2007).
48. Griffiths RW, Gilham DE, Dangoor A et al. Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: A potential target for T-cell-based immunotherapy. Br. J. Cancer 93(6), 670-677 (2005).
49. Vieweg J, Jackson A. Antigenic targets for renal cell carcinoma immunotherapy. Expert Opin. Biol. Ther. 4(11), 1791-1801 (2004).
50. Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E. Carbonic anhydrase IX in renal cell carcinoma: Implications for prognosis, diagnosis, and therapy. Eur. Urol. 58(1), 75-83 (2010).
51. O'Rourke MG, Johnson M, Lanagan C et al. Durable complete clinical responses in a Phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol. Immunother. 52(6), 387-395 (2003).
52. Mullins DW, Sheasley SL, Ream RM, Bullock TN, Fu YX, Engelhard VH. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J. Exp. Med. 198(7), 1023-1034 (2003).
53. Eggert AA, Schreurs MW, Boerman OC et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res. 59(14), 3340-3345 (1999).
54. Berntsen A, Trepiakas R, Wenandy L et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: A clinical Phase 1/2 trial. J. Immunother. 31, 771-780 (2008).
55. Kyte JA, Mu L, Aamdal S et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther. 13(10), 905-918 (2006).
56. De Vries IJ, Krooshoop DJ, Scharenborg NM et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 63(1), 12-17 (2003).
57. Aarntzen EH, Figdor CG, Adema GJ, Punt CJ, de Vries IJ. Dendritic cell vaccination and immune monitoring. Cancer Immunol. Immunother. 57(10), 1559-1568 (2008).
58. MartIn-Fontecha A, Sebastiani S, Hopken UE et al. Regulation of dendritic cell migration to the draining lymph node: Impact on T lymphocyte traffic and priming. J. Exp. Med. 198(4), 615-621 (2003).
59. Prins RM, Craft N, Bruhn KW et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: Relation to central nervous system antitumor immunity. J. Immunol. 176(1), 157-164 (2006).
60. de Vries IJ, Lesterhuis WJ, Barentsz JO et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat. Biotechnol. 23(11), 1407-1413 (2005).
61. Noh YW, Lim YT, Chung BH et al. Noninvasive imaging of dendritic cell migration into lymph nodes using nearinfrared fluorescent semiconductor nanocrystals. FASEB J. 22(11), 3908-3918 (2008).
62. Marten A, Flieger D, Renoth S et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical Phase I/II trial. Cancer Immunol. Immunother. 51(11-12), 637-644 (2002).
63. Kim JH, Lee Y, Bae YS et al. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin. Immunol. 125(3), 257-267 (2007).
64. Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115(12), 3623-3633 (2005).
65. Azuma T, Horie S, Tomita K et al. Dendritic cell immunotherapy for patients with metastatic renal cell carcinoma: University of Tokyo experience. Int. J. Urol. 9(6), 340-346 (2002).
66. Pandha HS, John RJ, Hutchinson J et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: A Phase I/II study. BJU Int. 94(3), 412-418 (2004).
67. Holtl L, Zelle-Rieser C, Gander H et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin. Cancer Res. 8(11), 3369-3376 (2002).
68. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25, 267-296 (2007).
69. Stewart TJ, Abrams SI. How tumours escape mass destruction. Oncogene 27(45), 5894-5903 (2008).
70. Pinzon-Charry A, Maxwell T, López JA. Dendritic cell dysfunction in cancer: A mechanism for immunosuppression. Immunol. Cell. Biol. 83(5), 451-461 (2005).
71. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4(12), 941-952 (2004).
72. Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer Res. 4(3), 585-593 (1998).
73. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 27(45), 5904-5912 (2008).
74. Koido S, Homma S, Takahara A et al. Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines. J. Biomed. Biotechnol. 2011, 910836 (2011).
75. Märten A, Ziske C, Schöttker B et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J. Immunother. 24(6), 502-510 (2001).
76. Sievers E, Albers P, Schmidt-Wolf IG, Märten A. Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma. J. Urol. 171(1), 114-119 (2004).
77. Schmidt J, Eisold S, Büchler MW, Märten A. Dendritic cells reduce number and function of CD4+CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma. Cancer Immunol. Immunother. 53(11), 1018-1026 (2004).
78. Hoos A, Parmiani G, Hege K et al. A clinical development paradigm for cancer vaccines and related biologics. J. Immunother. 30(1), 1-15 (2007).
79. Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC et al. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J. Immunother. 30(1), 116-122 (2007).
80. Marten A, Renoth S, Heinicke T et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical Phase I/II trial in patients with metastatic renal cell carcinoma. Hum. Gene Ther. 14(5), 483-494 (2003).
81. Wierecky J, Muller MR, Wirths S et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 66(11), 5910-5918 (2006).
82. Tatsugami K, Eto M, Harano M et al. Dendritic cell therapy in combination with interferon-a for the treatment of metastatic renal cell carcinoma. Int. J. Urol. 15(8), 694-698 (2008).
83. Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13(8), 859-875 (2008).
84. Schön MP, Schön M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 27(2), 190-199 (2008).
85. Bonehill A, Tuyaerts S, Van Nuffel AM et al. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol. Ther. 16(6), 1170-1180 (2008).
86. Ito F, Li Q, Shreiner AB et al. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res. 64(22), 8411-8419 (2004).
87. Ribas A, Comin-Anduix B, Chmielowski B et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin. Cancer Res. 15(19), 6267-6276 (2009).
88. Thompson RH, Webster WS, Cheville JC et al. B7-H1 glycoprotein blockade: A novel strategy to enhance immunotherapy in patients with renal cell carcinoma. Urology 66(5 Suppl.), S10-S14 (2005).
89. Tykodi SS, Voong LN, Warren EH. Combining allogeneic immunotherapy with an mTOR inhibitor for advanced renal cell carcinoma. Bone Marrow Transplant. 45(8), 1360-1362 (2010).
90. Ou X, Cai S, Liu P et al. Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT. J. Cancer Res. Clin. Oncol. 134(5), 525-533 (2008).
91. Flatekval GF, Sioud M. Modulation of dendritic cell maturation and function with mono- and bifunctional small interfering RNAs targeting indoleamine 2,3-dioxygenase. Immunology 128(Suppl. 1), E837-E848 (2009).
92. Ohkusu-Tsukada K, Ohta S, Kawakami Y, Toda M. Adjuvant effects of formalininactivated HSV through activation of dendritic cells and inactivation of myeloidderived suppressor cells in cancer immunotherapy. Int. J. Cancer 128(1), 119-131 (2011).
93. Liu JY, Wu Y, Zhang XS et al. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol. Immunother. 56(10), 1597-1604 (2007).
94. Rini BI, Sosman JA, Motzer RJ. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. BJU Int. 96, 286-290 (2005).
95. Soleimani A, Berntsen A, Svane IM, Pedersen AE. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate. Scand. J. Immunol. 70(5), 481-489 (2009).